Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
- Kingman Regional Medical Center — Kingman, Arizona
+ 809 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Locations: - Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
+ 664 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to der…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Locations: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
- Ironwood Cancer & Research Centers — Glendale, Arizona
+ 70 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Locations: - Research Site — Daphne, Alabama
- Research Site — Springdale, Arkansas
- Research Site — Duarte, California
+ 61 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Locations: - Southern Cancer Center — Daphne, Alabama
- Sutter Auburn Faith Hospital — Auburn, California
- La Hematology Oncology Medical Group — Glendale, California
+ 58 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- UC San Diego Health System - Encinitas — Encinitas, California
+ 55 more sites in the U.S.
Phase 3 Recruiting Industry
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced…
Sponsor: AstraZeneca
NCT ID: NCT04862663
Locations: - Research Site — Tucson, Arizona
- Research Site — Fountain Valley, California
- Research Site — Glendale, California
+ 51 more sites in the U.S.
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Locations: - The Dignity Health Cancer Institute — Phoenix, Arizona
- Disney Family Cancer Center — Burbank, California
- Scripps Health — La Jolla, California
+ 51 more sites in the U.S.
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Locations: - Southern Cancer Center — Mobile, Alabama
- City of Hope - Cancer Center Phoenix — Goodyear, Arizona
- Tucson Medical Center HealthCare — Tucson, Arizona
+ 48 more sites in the U.S.
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Locations: - Mayo Clinic Scottsdale - PPDS — Phoenix, Arizona
- Arizona Oncology Tucson - Wilmot — Tucson, Arizona
- University of Arizona Cancer Center — Tucson, Arizona
+ 45 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Locations: - Local Institution - 0303 — Hot Springs, Arkansas
- Helios Clinical Research — Cerritos, California
- Local Institution - 0307 — Cerritos, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Locations: - Clinical Trial Site — Hot Springs, Arkansas
- Clinical Trial Site — Beverly Hills, California
- Clinical Trial Site — San Francisco, California
+ 34 more sites in the U.S.